In SLE, two targets that are increasingly used are the DORIS 2021 Remission and the Lupus Low Disease Activity (LLDAS). T2T is more likely to be successful if the treating clinicians and the patients set the treatment goals together. What do our patients think about T2T and do they have any say/concern?
All News
Article
Article
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area; current epidemiology suggests person-to-person community spread.
Article
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty.
Article
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
MMWR: Monkeypox Outbreak in Nine States
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area.
https://t.co/Pr0n7pwAgS https://t.co/DvJtLq85E2
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ
Watch: #EULAR2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
https://t.co/HomsEG9CdX https://t.co/LdMa2FUe76
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
https://t.co/6Xdu3acGXN
@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/juFkMtF5hS
#EULAR2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
https://t.co/aTVKYhggGD
@doctorRBC @RichardPAConway https://t.co/kn3PkaFGSy
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/j4LJPZFqzY https://t.co/ABAbm3axSG
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/Miab1eiHZ6 https://t.co/n9IjPwqG2t
Watch this 4 minute video on Belimumab use in pregnancy featuring Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/8uRUIVURHF https://t.co/lbYwHFFJit
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT
Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p
Miss this week's TNR? Watch the playback.
https://t.co/LSlw939Vj2 https://t.co/K62afKWz95
Can we stop RA before it happens?
Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals.
https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT
Price of a newly launched drug increased from $2115 per year in 2008 to $180 007 per year in 2021. In 2008 only 9% of drug cost >$150k/yr; this rose to 47% by 2021. Greater increases seen w/ biologics, rare disease and nononcology drugs https://t.co/JaGzNqCxdF
Gout Undertreatment Persists
Despite updated gout management guidelines from EULAR and BSR, treatment of gout is suboptimal with regard to the use of urate-lowering therapy (ULT) and normalizing serum uric acid (< 6.0 mg/dl) levels.
https://t.co/qW7ZaXbnx3 https://t.co/ZBKIjuQp10
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR
Video: Residual Pain in RA
Dr. Maxime Dougados discusses OP0052 at #EULAR2022.
https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW


